SOCRA - Society of Clinical Research Associates Essential Study Documents Questions and Answers 1 — Questions and Answers
Question 1: A clinical trial protocol is amended to include a new secondary objective and an additional blood draw at Visit 3. According to ICH GCP, which of the following essential documents must be updated, approved by the IRB/IEC, and implemented by the site BEFORE the changes are enacted for any new or existing participants?
- The Investigator's Brochure and FDA Form 1572.
- The signed protocol, the informed consent form, and any other relevant written information for subjects. (Correct answer)
- The Delegation of Authority Log and the site's Standard Operating Procedures (SOPs).
- The Financial Disclosure Forms and the clinical trial agreement with the sponsor.
Correct answer: The signed protocol, the informed consent form, and any other relevant written information for subjects.
ICH GCP E6(R2) requires that any amendment to the protocol that affects the conduct of the trial or increases risk to subjects must be documented. A change in objectives and procedures necessitates updating the protocol itself and, crucially, the informed consent form (ICF) to ensure subjects are aware of the new procedures and can provide consent. These revised documents must be submitted to and approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before implementation.
Question 2: On an FDA Form 1572, the Principal Investigator (PI) signs to attest they will personally conduct or supervise the investigation. In Block #6, the PI lists the names of sub-investigators who will assist in the conduct of the trial. Which of the following individuals would typically NOT need to be listed in Block #6?
- A hospital pharmacist who is responsible for preparing and dispensing the investigational product according to a randomization schedule.
- A staff nurse who performs intermittent study assessments, such as vital signs, but does not make significant original contributions to the data. (Correct answer)
- A fellow in the PI's department who is delegated the responsibility of obtaining informed consent and evaluating adverse events.
- A co-investigator at a satellite clinic who will enroll subjects and conduct all study visits at that location.
Correct answer: A staff nurse who performs intermittent study assessments, such as vital signs, but does not make significant original contributions to the data.
FDA guidance on the Form 1572 clarifies that individuals who provide ancillary or intermittent care but do not make a direct and significant contribution to the data do not need to be listed in Block #6. A nurse taking vital signs falls into this category, whereas pharmacists preparing the investigational product and physicians/fellows performing key trial functions like consenting and safety evaluation are considered to have a direct and significant role.
Question 3: Which of the following essential documents is primarily intended to provide the investigator and other site staff with a comprehensive summary of the nonclinical and clinical data on the investigational product accumulated to date?
- The signed protocol agreement
- The FDA Form 1572
- The Investigator's Brochure (IB) (Correct answer)
- The IRB/IEC approval letter
Correct answer: The Investigator's Brochure (IB)
The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, key features of the protocol, such as the dose, dose frequency/interval, methods of administration, and safety monitoring procedures.
Question 4: According to ICH GCP E6(R2) Section 8, essential documents are grouped by their relevance before, during, and after the trial. Which set of documents must be on file at the investigator site BEFORE the clinical phase of the trial commences?
- Monitoring visit reports, completed CRFs, and signed informed consent forms.
- Final close-out report, audit certificates, and treatment allocation records.
- Subject screening log, investigational product accountability records, and documentation of protocol deviations.
- Signed protocol, IRB/IEC approval of the protocol and ICF, and the current Investigator's Brochure. (Correct answer)
Correct answer: Signed protocol, IRB/IEC approval of the protocol and ICF, and the current Investigator's Brochure.
ICH GCP E6(R2) Section 8.2 outlines the documents that should be on file before the trial's clinical phase begins. This includes documentation of investigator and sponsor agreement to the protocol, IRB/IEC approval for the study documents (protocol, ICF, recruitment materials), and the current Investigator's Brochure to provide scientific information to the investigator.
Question 5: A clinical investigator is participating in a pivotal Phase III drug trial intended to support a marketing application. According to 21 CFR Part 54, the investigator must provide the sponsor with sufficient financial information. The investigator must promptly update this information if any relevant changes occur during the investigation and for what period of time following the completion of the study?
- For 6 months following study completion.
- For 1 year following study completion. (Correct answer)
- For 2 years following study completion.
- There is no requirement to update after study completion.
Correct answer: For 1 year following study completion.
According to 21 CFR 54.4(b), the investigator is required to provide the sponsor with accurate financial information and must 'promptly update this information if any relevant changes occur in the course of the investigation or for 1 year following completion of the study.' This ensures that the sponsor has current information when submitting the marketing application to the FDA.
Question 6: An Investigator Site File (ISF) and a Trial Master File (TMF) both contain essential documents. What is the primary distinction between the two?
- The ISF is maintained by the sponsor and the TMF is maintained by the investigator.
- The ISF contains only source documents, while the TMF contains only regulatory documents.
- The ISF is maintained by the investigator at the site level, while the TMF is maintained by the sponsor and contains documents from all sites. (Correct answer)
- The ISF is audited by the IRB/IEC, and the TMF is audited by the FDA.
Correct answer: The ISF is maintained by the investigator at the site level, while the TMF is maintained by the sponsor and contains documents from all sites.
The Investigator Site File (ISF) is the collection of essential documents held by the investigator at the clinical site, demonstrating the trial was conducted according to the protocol and regulations. The Trial Master File (TMF) is the sponsor's comprehensive archive, consolidating documents from all participating sites to permit evaluation of the trial's conduct and data quality.
SOCRA - Society of Clinical Research Associates Essential Study Documents Questions and Answers 1
A clinical trial protocol is amended to include a new secondary objective and an additional blood draw at Visit 3.
According to ICH GCP, which of the following essential documents must be updated, approved by the IRB/IEC, and implemented by the site BEFORE the changes are enacted for any new or existing participants?